Ataxia is a set of degenerative illnesses involving the cerebellum in the brain, which is in charge of controlling bodily balance and coordination. Ataxia does not have a cure; only its symptoms, such as weakness and trouble moving, may be addressed. Spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and other kinds of ataxia exist.
Spinocerebellar ataxia (SCA) is caused by genetic abnormalities that weaken nerve fibers that convey neural impulses in the brain, leading to cerebellum degeneration. People with this disorder frequently experience issues with mobility and balance, as well as muscle weakness and trouble with eye movement, among other symptoms. SCA is a progressive kind of ataxia that can strike at any age. Friedreich's ataxia is a kind of hereditary ataxia in which sufferers have muscular stiffness and loss of feeling, weakness across the body, a heart problem (hypertrophic cardiomyopathy), and other symptoms in addition to usual movement-related symptoms.
The worldwide ataxia market is predicted to be worth US$ 30,880.5 million in 2021, with a CAGR of 9.4 percent over the forecast period (2021-2028).
Key market participants are focused on filing applications for drug therapy approved for the treatment of ataxia, which is projected to fuel development in the worldwide ataxia market over the forecast period.
For example, in March 2019, Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical firm located in the United States, began a Phase III clinical study of its third-generation prodrug troriluzole, which is designed for the treatment of spinocerebellar ataxia.